Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of inhibition of VCP on gene expression during colorectal cancer progression of HCT116 cells

ABSTRACT: To investigate the signaling patheway of VCP regulation PD-L1 in colorectal cancer cells, HCT116 cells were treated with CB-5083. We then performed gene expression profiling analysis using data obtained from RNA-seq of 3 different cells CB-5083 treatment and untreatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE201778 | GEO | 2023/10/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

HCT116 cells treated with the p97 inhibitior CB-5083

Project description:The goal of this study was to analyze differential gene expression 8 hr after treatment of CB-5083, a small molecule inhibitor of p97 (VCP), in HCT116 cells grown in culture. DMSO treated cells were compared to cells treated with 1uM CB-5083 after 8 hr.

2015-11-09 | E-GEOD-73588 | biostudies-arrayexpress

HCT116 cells treated with the p97 inhibitior CB-5083

Project description:The goal of this study was to analyze differential gene expression 8 hr after treatment of CB-5083, a small molecule inhibitor of p97 (VCP), in HCT116 cells grown in culture.

2015-11-09 | GSE73588 | GEO

Effect of overexpression of VCP on gene expression during colorectal cancer progression of HCT116 cells

Project description:To investigate the function of VCP in the colorectal cancer progression, we established HCT116 cell lines overexpressing VCP. We then performed gene expression profiling analysis using data obtained from RNA-seq of 3 different cells overexpressing VCP and control vector.

2023-07-18 | GSE201660 | GEO

Genome-wide maps of chromatin state in HCT116 cells expressing Flag-tagged VCP

Project description:Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) for VCP and Flag in HCT116 cells expressing Flag-tagged VCP.

2023-07-18 | GSE201200 | GEO

p97/VCP as a therapy target for developing drugs against human coronavirus

Project description:Understanding how human coronavirus dysregulate host proteome during infection in human cells will identify general pathways that are common to coronavirus infection. NMS-873 is an allosteric p97/VCP ATPase inhibitor and was show to have antiviral effect in multiple viruses including SARS-CoV2. We first demonstrated that genetic knock down of p97 reduced HCoV-229E, HCoV-OC43 infection and secretion. To investigate how p97/VCP assists virus infection, we used unbiased quantitative proteomics to compare dysregulated proteomes caused by HCoV-229E, HCoV-OC43 and SARS-CoV2 infection. We then compared dysregulated proteomes after HCoV-229E and HCoV-OC43 infection with and without p97 knockdown. Moreover, we elucidated the impact of p97 on different stages of viral life cycle using two potent p97 inhibitors, CB-5083 and NMS-873 and demonstrate their can block HCoV replication. Together, our data provide insights to repurpose potential cancer drugs that target the essential host protein p97/VCP.

2021-11-03 | PXD026216 | Pride

Homo sapiens

Project description:HCT116 cells treated with the p97 inhibitior CB-5083

| PRJNA297366 | ENA

Gene expression profile of multiple myeloma cell lines treated with CB-5083

Project description:The goal was to determine the gene expression differences between CB-5083 and Bortezomib treated multiple myeloma cell lines Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting the ubiquitin proteasome system (UPS) and CB-5083, a first in class inhibitor of p97, has demonstrated broad antitumor activity in a range of both hematological and solid tumor models. Here, we show that CB-5083 has robust activity against multiple myeloma (MM) cell lines and a number of in vivo MM models. Treatment with CB-5083 is associated with accumulation of ubiquitinated proteins, induction of the unfolded protein response (UPR) and apoptosis. CB-5083 decreases viability in MM cell lines and patient derived MM cells, including those with background proteasome inhibitor (PI) resistance. CB-5083 has a unique mechanism of action that combines well with PIs which is likely owing to the p97-dependent retro-translocation of the transcription factor, Nrf1, which transcribes proteasome subunit genes following exposure to a PI. In vivo studies using clinically relevant MM models demonstrate that single-agent CB-5083 inhibits tumor growth and combines well with MM standard of care agents. Our preclinical data demonstrate the efficacy of CB-5083 in several MM disease models and provide the rationale for clinical evaluation as monotherapy and in combination in MM.

2017-10-26 | GSE101923 | GEO

Effect of inhibition of VCP on gene expression during colorectal cancer progression of HCT116 cells

Project description:Effect of inhibition of VCP on gene expression during colorectal cancer progression of HCT116 cells

| PRJNA833032 | ENA

Effect of overexpression of VCP on gene expression during colorectal cancer progression of HCT116 cells

Project description:Effect of overexpression of VCP on gene expression during colorectal cancer progression of HCT116 cells

| PRJNA832589 | ENA

Genome-wide maps of chromatin state in HCT116 cells expressing Flag-tagged VCP

Project description:Genome-wide maps of chromatin state in HCT116 cells expressing Flag-tagged VCP

| PRJNA830344 | ENA